Multi-million USD grant agreement with Washington University in St. Louis – C&G works for Kompania Górnicza

In May 2024, our long-standing Client, Kompania Górnicza, finalized a Grant Agreement with Washington University in St. Louis, providing funding in the amount of several million dollars for cutting-edge research on gene therapy for CRX-linked dominant retinopathies. That research is led by world-renowned expert Shiming Chen, PhD, a professor of Ophthalmology & Visual Sciences at Washington University School of Medicine in St. Louis.

Dr. Chen is the global scientific leader in the study of disease caused by CRX mutations. She has dedicated her career to CRX mutation-associated blinding diseases and together with her team seeks to bring hope to affected individuals and families around the world. Consistently ranked among the top U.S. medical schools for research, Washington University School of Medicine provides state-of-the-art facilities for conducting innovative research, including studies aimed at developing the gene therapy. The medical school is part of Washington University, a premier university widely known for its leadership in teaching, research, patient care and service to society. Learn more about the Chen Lab.

Over the past few months, the C&G team has provided comprehensive legal guidance and support to Kompania Górnicza throughout the negotiation process, ensuring a smooth execution of the Grant Agreement.

Our team consisted of Piotr Gałuszyński, Urszula Rachwol and Iga Karasińska. The Client was also supported by Andersen Tax Representation, Katarzyna Chrapowicka, Marcin Matyka on the tax aspects of the agreement. Formedis, Paweł Magdziarz, Piotr Magdziarz, Dominik Dziurda supported our Client with analysis on research and its future prospects.